[go: up one dir, main page]

SE9900672D0 - Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula - Google Patents

Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

Info

Publication number
SE9900672D0
SE9900672D0 SE9900672A SE9900672A SE9900672D0 SE 9900672 D0 SE9900672 D0 SE 9900672D0 SE 9900672 A SE9900672 A SE 9900672A SE 9900672 A SE9900672 A SE 9900672A SE 9900672 D0 SE9900672 D0 SE 9900672D0
Authority
SE
Sweden
Prior art keywords
prevention
composition
scar formation
glaucoma filtration
drainage fistula
Prior art date
Application number
SE9900672A
Other languages
English (en)
Inventor
Johan Stjernschantz
Bahram Resul
Original Assignee
Synphora Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synphora Ab filed Critical Synphora Ab
Priority to SE9900672A priority Critical patent/SE9900672D0/sv
Publication of SE9900672D0 publication Critical patent/SE9900672D0/sv
Priority to CA002363131A priority patent/CA2363131A1/en
Priority to EP00911536A priority patent/EP1161245B1/en
Priority to US09/913,849 priority patent/US6495563B1/en
Priority to AT00911536T priority patent/ATE279197T1/de
Priority to JP2000600651A priority patent/JP2003521467A/ja
Priority to AU33402/00A priority patent/AU767411B2/en
Priority to DE60014869T priority patent/DE60014869T2/de
Priority to PCT/SE2000/000357 priority patent/WO2000050040A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9900672A 1999-02-25 1999-02-25 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula SE9900672D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9900672A SE9900672D0 (sv) 1999-02-25 1999-02-25 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
CA002363131A CA2363131A1 (en) 1999-02-25 2000-02-23 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
EP00911536A EP1161245B1 (en) 1999-02-25 2000-02-23 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
US09/913,849 US6495563B1 (en) 1999-02-25 2000-02-23 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
AT00911536T ATE279197T1 (de) 1999-02-25 2000-02-23 Methode und zusammenstellung zur prophylaxe der narbenbildung bei glaukomatösen filtrationsblasen und drainagefisteln
JP2000600651A JP2003521467A (ja) 1999-02-25 2000-02-23 緑内障の濾過ブレブおよびドレナージフィステルにおける瘢痕形成の予防のための方法および組成物
AU33402/00A AU767411B2 (en) 1999-02-25 2000-02-23 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
DE60014869T DE60014869T2 (de) 1999-02-25 2000-02-23 Methode und zusammenstellung zur prophylaxe der narbenbildung bei glaukomatösen filtrationsblasen und drainagefisteln
PCT/SE2000/000357 WO2000050040A1 (en) 1999-02-25 2000-02-23 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900672A SE9900672D0 (sv) 1999-02-25 1999-02-25 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

Publications (1)

Publication Number Publication Date
SE9900672D0 true SE9900672D0 (sv) 1999-02-25

Family

ID=20414625

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900672A SE9900672D0 (sv) 1999-02-25 1999-02-25 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

Country Status (9)

Country Link
US (1) US6495563B1 (sv)
EP (1) EP1161245B1 (sv)
JP (1) JP2003521467A (sv)
AT (1) ATE279197T1 (sv)
AU (1) AU767411B2 (sv)
CA (1) CA2363131A1 (sv)
DE (1) DE60014869T2 (sv)
SE (1) SE9900672D0 (sv)
WO (1) WO2000050040A1 (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981880A (en) 1969-03-14 1976-09-21 The Upjohn Company Racemic prostaglandins of the 2-series and analogs thereof
US3954844A (en) 1975-01-03 1976-05-04 G. D. Searle & Co. (5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9.13-trien-1-oic acid and esters
JPS58216155A (ja) 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
ES2053458T3 (es) * 1986-03-13 1994-08-01 Univ Columbia Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma.
ATE108330T1 (de) 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
ATE420857T1 (de) * 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
ATE111736T1 (de) 1988-10-01 1994-10-15 R Tech Ueno Ltd Okulare hypotensive mittel.
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
SE9401087D0 (sv) 1994-03-31 1994-03-31 Pharmacia Ab New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins

Also Published As

Publication number Publication date
JP2003521467A (ja) 2003-07-15
CA2363131A1 (en) 2000-08-31
AU767411B2 (en) 2003-11-06
AU3340200A (en) 2000-09-14
ATE279197T1 (de) 2004-10-15
EP1161245B1 (en) 2004-10-13
WO2000050040A1 (en) 2000-08-31
DE60014869T2 (de) 2006-03-09
WO2000050040A8 (en) 2003-02-06
EP1161245A1 (en) 2001-12-12
DE60014869D1 (de) 2004-11-18
US6495563B1 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
AU2002338483A1 (en) Drainage implant for draining aqueous humour from the anterior aqueous chamber of the eye into schlemm's canal
ATE336247T1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
WO2000037056A3 (en) Composition and method for treating glaucoma
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
WO2003047513A3 (en) Method for treating ocular hypertension
DE69019774D1 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
BR0210855A (pt) Método de fabricação de formulações de liberação prolongada
MA25823A1 (fr) Compositions pour le traitement de l'eau.
DE60236639D1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
WO2001064200A3 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0002660D0 (en) Method of stabilizing a hydrophobin-containing solution and a method of coatinga surface with a hydrophobin
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DK1395263T3 (da) 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk
WO2002102978A3 (en) Human growth hormone antagonists
EP1664011A4 (en) OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
SE9900672D0 (sv) Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
RU99123236A (ru) Способ хирургического лечения открытоугольной глаукомы
DK1225890T3 (da) Rivastigmin til behandling af öjensygdomme
WO2001010848A3 (en) Diazocin-dione derivatives and their use s tryptase inhibitors
NO20023343D0 (no) Belegging av implanterbare oftalmiske linser for å redusere kantblending
RU2000106845A (ru) Способ хирургического лечения открытоугольной далекозашедшей и терминальной глаукомы
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
ATE496619T1 (de) Zusammensetzungen, die phospholipase c inhibitoren enthalten und verfahren zur erhöhung parazellulärer permeabilität der epithelbarriere und endothelbarriere